MELISSA GIMENEZ: Open Payments
NPI 1447880745 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,147 in 160 payments from 16 companies in 2025. Trend: 2023 $290 · 2024 $1,637 · 2025 $3,147
Food & beverage: $3,118Education: $29
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 39 | $612 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 24 | $400 |
| Otsuka America Pharmaceutical, Inc. | 18 | $380 |
| Axsome Therapeutics, Inc. | 14 | $323 |
| Vanda Pharmaceuticals Inc. | 17 | $286 |
| Neurocrine BioSciences, Inc. | 9 | $231 |
| Teva Pharmaceuticals USA, Inc. | 9 | $222 |
| Janssen Pharmaceuticals, Inc | 6 | $178 |
| Alkermes, Inc. | 8 | $150 |
| Lundbeck LLC | 4 | $116 |
Products named: VRAYLAR, CAPLYTA, REXULTI, Auvelity, FANAPT, INGREZZA, AUSTEDO XR, ARISTADA.
Industry payments across TX — which companies pay providers there.
